PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.90%
Both companies show declining cash positions (-19.90% vs TRVN's -11.51%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-19.90%
Cash + STI yoy ≥ 1.5x TRVN's -11.51%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.69%
1.25-1.5x TRVN's -13.07%. Bruce Berkowitz checks if strong current asset growth is used effectively.
6.10%
Below half TRVN's 51.42%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRVN and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.84%
Below half of TRVN's 50.19%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-18.44%
1.25-1.5x TRVN's -12.67%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
65.60%
Above 1.5x TRVN's 12.07%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRVN and the company show zero Deferred Revenue (Current) Growth.
-13.55%
Less than half of TRVN's 5.23%. David Dodd sees fewer expansions in other current obligations.
-8.01%
Less than half of TRVN's 44.90%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.01%
Less than half of TRVN's 73.10%. David Dodd sees far fewer liability expansions relative to competitor.
7.31%
Above 1.5x TRVN's 0.07%. Michael Burry suspects heavy new equity expansion or dilution.
-7.62%
0.5-0.75x TRVN's -15.06%. Martin Whitman is wary of weaker retention or lower profitability.
-130.04%
Less than half of TRVN's 12.67%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-45.22%
≥ 1.5x TRVN's -18.75%. David Dodd sees stronger capital base growth than competitor.
-18.44%
1.25-1.5x TRVN's -12.67%. Bruce Berkowitz checks if expansions are well-justified by ROI.
-100.00%
Both TRVN and the company show zero Total Investments Growth.
-100.00%
Higher Total Debt Growth compared to TRVN's zero value, indicating worse performance.
19.60%
1.25-1.5x TRVN's 13.70%. Martin Whitman is wary of heavier net leverage vs. competitor.